Table 3.
Clinical and Laboratory Characteristics above and below the median for Relative Wall Thickness (RWT).
| RWT ≥0.74 | RWT <0.74 | P values | |
|---|---|---|---|
| Age (years) | 62 ± 10.1 | 61 ± 9.9 | 0.474 |
| Sex: Male (%) Female (%) | 47 (59.5%) 32 (40.5%) | 50 (64%) 28 (35.9%) | 0.552 |
| Race: White (%) | 55 (72.4%) | 64 (83.1%) | 0.081 |
| Systolic blood pressure (mmHg) | 113.4 ± 21.86 | 110.6 ± 14.47 | 0.339 |
| Diastolic blood pressure (mmHg) | 73.7 ± 10.22 | 71.9 ± 9.0 | 0.260 |
| Pulse rate, beats/min | 84.9 ± 16.9 | 81.9 ± 13.8 | 0.238 |
| Body mass index (kg/m2) | 25.4 ± 3.9 | 26.0 ± 5.5 | 0.411 |
| Hypertension (%) | 15 (19%) | 18 (23.1%) | 0.529 |
| Diabetes mellitus (%) | 3 (3.8%) | 5 (6.4%) | 0.697 |
| Coronary artery disease (%) | 9 (11.4%) | 20 (26%) | 0.019* |
| Atrial fibrillation (%) | 20 (25.3%) | 20 (26%) | 0.925 |
| Lambda light chain (%) | 63 (80.8%) | 70 (89.7%) | 0.114 |
| Kidney involvement (%) | 33 (41.8) | 26 (33.8%) | 0.303 |
| NYHA class | 3 (1–4)† | 2.5 (2–3.5)† | 0.059 |
| NYHA class 3/4 | 44 (55.7%) | 32 (41%) | 0.066 |
| QRS duration (ms) on EKG | 97.4 ± 25.86 | 101.9 ± 25.15 | 0.275 |
| Medication Use: | |||
| Aldactone (%) | 19 (24.1%) | 16 (20.5%) | 0.594 |
| Loop diuretic (%) | 67 (84.8%) | 63 (81.8%) | 0.616 |
| Thiazide diuretic (%) | 8 (10.1%) | 11 (14.3%) | 0.427 |
| Beta blocker (%) | 29 (36.7%) | 34 (43.6%) | 0.379 |
| ACE-I/ARB (%) | 15 (19%) | 15 (19.2%) | 0.969 |
| Anticoagulants (%) | 15 (19%) | 25 (32.1%) | 0.060 |
| Laboratory Data: | |||
| BNP (pg/mL) | 739 (372–1368)† | 556 (241–972)† | 0.107 |
| Troponin I (ng/mL) | 0.57 ± 1.39 | 0.22 ± 0.33 | 0.089 |
| Creatinine kinase (U/L) | 135 ± 20.3 | 103 ± 9 | 0.161 |
| C-reactive protein (mg/L) | 6.53 ± 7.43 | 8.68 ± 14.15 | 0.244 |
| Hemoglobin (g/dl) | 13.61 ± 1.72 | 13.04 ± 1.65 | 0.035* |
| Sodium (mmol/L) | 138.5 ± 3.9 | 138.7 ± 3.6 | 0.729 |
| MDRD eGFR (ml/min/1.73 m2) | 67.9 ± 24.8 | 66.9 ± 21.7 | 0.792 |
| Uric acid (mg/dl) | 7.99 ± 2.49 | 7.56 ± 2.52 | 0.297 |
| Alkaline phosphatase (U/L) | 131.5 ± 77.1 | 142.7 ± 95.4 | 0.431 |
| Free kappa light chains (mg/L) | 163.7 ± 478.3 | 63.45 ± 228.7 | 0.096 |
| Free lambda light chains (mg/L) | 401.3 ± 475.7 | 378.2 ± 522.5 | 0.773 |
| Free light chains kappa/lambda ratio | 15.51 ± 52.79 | 7.42 ± 31.72 | 0.247 |
| dFLC (mg/L) | 536.8 ± 581.4 | 418.5 ± 535.0 | 0.188 |
Data are expressed as mean ± SD or median (range) for continuous variables or numbers (%) for categorical variables. †Median (IQR range). AL indicates immunoglobulin light chain amyloidosis; NYHA, New York Heart Association; EKG, electrocardiogram; MDRD eGFR, glomerular filtration rate by Modification of Diet in Renal Disease equation; BNP, brain natriuretic peptide; ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin receptor blocker; dFLC, difference between involved and uninvolved light chains; EKG, electrocardiogram. Anticoagulants include warfarin and non-vitamin K antagonist oral anticoagulants.